Work

Neoadjuvant Nivolumab +/- Ipilimumab in Patients with Oral Cavity Cancer

Year: 2020

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2019.11.388

Authors: J.D. Schoenfeld, G.J. Hanna, V. Jo, S. Criscitiello, B. Rawal, P.S. Catalano, N. Chau, J. Lorch, J. Kass, D. Annino, L. Goguen, B. Ross, D.N. Margalit, R.B. Tishler, R. Uppaluri, R.I. Haddad

Institutions: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Harvard University, BC Cancer Agency

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3010824241

FWCI: 0.182

Cites:

Cited by: 2

Related to: 10